Myriad Sponsors Clinical Trial
Salt Lake City, Utah-based Myriad Genetics announced this morning that the company is sponsoring a clinical trial of patients with pancreatic cancer. The study, run by researchers at Johns Hopkins University, will enroll patients with untreated, advanced or recurrent pancreatic cancer and a mutation in the BRCA2 gene. Myriad said that the trial will determine whether the sensitivity of the pancreatic cancer to its agent mitomycin-C holds true in humans as it did in earlier studies.
posted on Tuesday, October 24, 2006
Related companies:
Myriad Capital
Related stories:
> Myriad Completes Phase 3 Trial Enrollment
> Myriad Announces Positive Study Results On Alzheimer's Drug
> Myriad Genetics Buys Counsyl For $375M
> Myriad Genetics Buys Sividon Diagnostics
> Myriad Genetics Buys Genetic Marker Technology
Techrockies.com Home